Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines-Reference-Cited by-同舟云学术

Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines

Published:2022-08-01 Issue:8 Volume:7 Page:836
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Mortensen Martin Bødtker¹²³⁴,Tybjærg-Hansen Anne³⁴⁵,Nordestgaard Børge G.²³⁴

Affiliation:

1. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark

2. Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark

3. The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark

4. Department of Internal Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

5. Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2793729/jamacardiology_mortensen_2022_oi_220031_1659374725.25982.pdf

Reference27 articles.

1. Comparison of five major guidelines for statin use in primary prevention in a contemporary general population.;Mortensen;Ann Intern Med,2018

2. Cardiovascular risk prediction: basic concepts, current status, and future directions.;Lloyd-Jones;Circulation,2010

3. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.;Conroy;Eur Heart J,2003

4. Limitations of the SCORE-guided European guidelines on cardiovascular disease prevention.;Mortensen;Eur Heart J,2017

5. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.;Goff;J Am Coll Cardiol,2014

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allgemeine Abschätzung des kardiovaskulären Risikos;Angewandte Nuklearmedizin;2024-09

2. Age and sex specific thresholds for risk stratification of cardiovascular disease and clinical decision making: prospective open cohort study;BMJ Medicine;2024-08

3. Adoption of the PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) Risk Algorithm;JACC: Advances;2024-08

4. Type 3 resistant starch from Canna edulis reduce lipid levels in patients with mild hyperlipidemia through altering gut microbiome: A double- blind randomized controlled trial;Pharmacological Research;2024-07

5. Eligibility for lipid-lowering therapy when applying systemic coronary risk estimation 2 according to guidelines on apparently healthy middle-aged individuals;European Journal of Preventive Cardiology;2024-06-06